Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 26, 2020 08:00 ET | Source: Passage Bio

Passage Bio Added to Russell 2000 Index

PHILADELPHIA, June 26, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
June 04, 2020 08:00 ET | Source: Passage Bio

Passage Bio to Present at Goldman Sachs 41st Annual Global Healthcare Conference

PHILADELPHIA, June 04, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
May 21, 2020 08:00 ET | Source: Passage Bio

Passage Bio Receives Rare Pediatric Disease Designation for PBGM01 for Patients with GM1 Gangliosidosis

PHILADELPHIA, May 21, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system...
May 12, 2020 17:00 ET | Source: Passage Bio

Passage Bio Announces Presentation of Data from Animal Models of Krabbe Disease at the American Society of Gene & Cell Therapy (ASGCT) 23rd Annual Meeting

– Preclinical data from University of Pennsylvania’s Gene Therapy Program demonstrate single injection of AAVhu68 carrying a functional GALC gene resulted in normalization of GALC enzyme activity and...
May 11, 2020 07:00 ET | Source: Passage Bio

Passage Bio Reports First Quarter 2020 Financial Results and Recent Business Highlights

– Expansion of gene therapy collaboration with University of Pennsylvania’s Gene Therapy Program extends collaboration by three additional years and adds five new programs – – Orphan Drug...
May 07, 2020 07:30 ET | Source: Passage Bio

Passage Bio Announces Expansion of Gene Therapy Collaboration with University of Pennsylvania

Option to license an additional five programs for a total of seventeenExtended option and research term to allow for collaboration through 2025Exclusive rights to certain technologies resulting from...
May 04, 2020 08:00 ET | Source: Passage Bio

Passage Bio to Report First Quarter 2020 Financial Results on May 11, 2020

PHILADELPHIA, May 04, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system...
April 21, 2020 08:00 ET | Source: Passage Bio

FDA Grants Passage Bio Orphan Drug Designation for PBGM01 for Treatment of Infantile GM1 Gangliosidosis

PHILADELPHIA, April 21, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
April 08, 2020 08:00 ET | Source: Passage Bio

Passage Bio to Present at 19th Annual Needham Healthcare Conference

PHILADELPHIA, April 08, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
March 27, 2020 08:00 ET | Source: Passage Bio

Passage Bio to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day

PHILADELPHIA, March 27, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...